Top

Published in:

Open Access 12-05-2023 | ORIGINAL RESEARCH

Intravenous Immunoglobulin Treatment Patterns and Outcomes in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A US Claims Database Analysis

Authors: Colin Anderson-Smits, Mary E. Ritchey, Zhongwen Huang, Shailesh Chavan, Nizar Souayah, Hakan Ay, J. Bradley Layton

Published in: Neurology and Therapy | Issue 4/2023

Abstract

Introduction

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare progressive or relapsing inflammatory disease. Intravenous immunoglobulin (IVIG) is recommended as a first-line therapy. The aim of this study was to describe real-world treatment patterns and outcomes of patients with CIDP in the Define initiating IVIG treatment.

Methods

This cohort study used health insurance claims data from the Merative MarketScan Research Databases (2008–2018). Adult patients (≥ 18 years old) with CIDP without prior immunoglobulin treatment were identified using International Statistical Classification of Diseases and Related Health Problems (ICD) codes, and patients subsequently initiating IVIG were included in the analysis. Real-world IVIG treatment patterns and treatment and safety outcomes (assessed via ICD codes) were described.

Results

In total, 3975 patients (median age 58 years) with CIDP who initiated IVIG were identified. After the initial IVIG loading period, patients received IVIG at a median dosing interval of 21 days (quartile [Q]1, Q3: 7, 28), and continued treatment for a median of 129 days (Q1, Q3: 85, 271). After the 2-year follow-up period, 55% of patients had discontinued all IVIG treatment; more than one-half of these discontinuations occurred within 4 months. Diagnoses of impaired functional status were evident in more than 30% of patients at baseline, but at lower rates during follow-up. Rates of new-onset safety outcomes after IVIG treatment were low.

Conclusion

This real-world analysis of IVIG treatment patterns and treatment and safety outcomes of patients with CIDP who initiated IVIG highlights the unmet need for improved long-term management. Further research is needed to evaluate the use of functional status measures as endpoints for immunoglobulin treatment effectiveness.

Available only for authorised users

Boukhris S, Magy L, Gallouedec G, et al. Fatigue as the main presenting symptom of chronic inflammatory demyelinating polyradiculoneuropathy: a study of 11 cases. J Peripher Nerv Syst. 2005;10(3):329–37. https://doi.org/10.1111/j.1085-9489.2005.10311.x.CrossRefPubMed

Guptill JT, Bromberg MB, Zhu L, et al. Patient demographics and health plan paid costs in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2014;50(1):47–51. https://doi.org/10.1002/mus.24109.CrossRefPubMed

Merkies IS, Kieseier BC. Fatigue, pain, anxiety and depression in Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. Eur Neurol. 2016;75(3–4):199–206. https://doi.org/10.1159/000445347.CrossRefPubMed

Westblad ME, Forsberg A, Press R. Disability and health status in patients with chronic inflammatory demyelinating polyneuropathy. Disabil Rehabil. 2009;31(9):720–5. https://doi.org/10.1080/09638280802306497.CrossRefPubMed

Koike H, Nishi R, Ikeda S, et al. Ultrastructural mechanisms of macrophage-induced demyelination in CIDP. Neurology. 2018;91(23):1051–60.CrossRefPubMed

Querol L, Crabtree M, Herepath M, et al. Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP). J Neurol. 2020;268:3706–16. https://doi.org/10.1007/s00415-020-09998-8.CrossRefPubMedPubMedCentral

Gorson KC. An update on the management of chronic inflammatory demyelinating polyneuropathy. Ther Adv Neurol Disord. 2012;5(6):359–73. https://doi.org/10.1177/1756285612457215.CrossRefPubMedPubMedCentral

Chan YC, Wilder-Smith E. Predicting treatment response in chronic, acquired demyelinating neuropathies. Expert Rev Neurother. 2006;6(10):1545–53. https://doi.org/10.1586/14737175.6.10.1545.CrossRefPubMed

Van den Bergh PY, Hadden RD, Bouche P, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. Eur J Neurol. 2010;17(3):356–63. https://doi.org/10.1111/j.1468-1331.2009.02930.x.CrossRefPubMed

10.

Yasir M, Goyal A, Bansal P, et al. Corticosteroid adverse effects. [Updated 2020 Jul 4]. Treasure Island (FL): StatesPearls; 2020. https://www.ncbi.nlm.nih.gov/books/NBK531462/.

11.

Eftimov F, Winer JB, Vermeulen M, et al. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2013; 12:CD001797; doi: https://doi.org/10.1002/14651858.CD001797.pub3.

12.

Harbo T, Andersen H, Hess A, et al. Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. Eur J Neurol. 2009;16(5):631–8. https://doi.org/10.1111/j.1468-1331.2009.02568.x.CrossRefPubMed

13.

Hughes R, Bensa S, Willison H, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 2001;50(2):195–201. https://doi.org/10.1002/ana.1088.CrossRefPubMed

14.

Hughes RA. Systematic reviews of treatment for chronic inflammatory demyelinating neuropathy. Rev Neurol (Paris). 2002;158(12 Pt 2):S32–6.PubMed

15.

Hughes RA, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 2008;7(2):136–44. https://doi.org/10.1016/S1474-4422(07)70329-0.CrossRefPubMed

16.

Kuitwaard K, van den Berg LH, Vermeulen M, et al. Randomised controlled trial comparing two different intravenous immunoglobulins in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry. 2010;81(12):1374–9. https://doi.org/10.1136/jnnp.2010.206599.CrossRefPubMed

17.

Leger JM, De Bleecker JL, Sommer C, et al. Efficacy and safety of Privigen® in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label phase III study (the PRIMA study). J Peripher Nerv Syst. 2013;18(2):130–40. https://doi.org/10.1111/jns5.12017.CrossRefPubMedPubMedCentral

18.

Mendell JR, Barohn RJ, Freimer ML, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 2001;56(4):445–9. https://doi.org/10.1212/wnl.56.4.445.CrossRefPubMed

19.

Nobile-Orazio E, Cocito D, Jann S, et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol. 2012;11(6):493–502. https://doi.org/10.1016/S1474-4422(12)70093-5.CrossRefPubMed

20.

Oaklander AL, Lunn MP, Hughes RA, van Schaik IN, Frost C, Chalk CH. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. Cochrane Database Syst Rev. 2017;1:CD010369. https://doi.org/10.1002/14651858.CD010369.pub2.

21.

Patwa HS, Chaudhry V, Katzberg H, et al. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2012;78(13):1009–15. https://doi.org/10.1212/WNL.0b013e31824de293.CrossRefPubMed

22.

Van Schaik IN, Winer JB, De Haan R, et al. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2002;2:CD001797. https://doi.org/10.1002/14651858.CD001797.

23.

Privigen prescribing information. 2019. http://labeling.cslbehring.com/PI/US/Privigen/EN/Privigen-Prescribing-Information.pdf. Accessed 6 Aug 2020.

24.

Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force - Second Revision. J Peripher Nerv Syst. 2021;26(3):242–68. https://doi.org/10.1111/jns.12455.CrossRefPubMed

25.

Gammaked prescribing information. 2017. http://www.gammaked.com/clientuploads/2017%20PI/GM-0559-00-2018B_GAMMAKED_Promotional_PI_3045813-3045814_Web_21031A.pdf. Accessed 6 Aug 2020.

26.

Gamunex-C prescribing information. 2020. https://www.gamunex-c.com/documents/27482625/27482925/Gamunex-C+Prescribing+Information.pdf/9258bd0f-4205-47e1-ab80-540304c1ff8e. Accessed 6 Aug 2020.

27.

Guptill JT, Runken MC, Eaddy M, et al. Treatment patterns and costs of chronic inflammatory demyelinating polyneuropathy: a claims database analysis. Am Health Drug Benefits. 2019;12(3):127–35.PubMedPubMedCentral

28.

Lopate G, Pestronk A, Al-Lozi M. Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone. Arch Neurol. 2005;62(2):249–54. https://doi.org/10.1001/archneur.62.2.249.CrossRefPubMed

29.

Lucke IM, Adrichem ME, Wieske L, et al. Intravenous immunoglobulins in patients with clinically suspected chronic immune-mediated neuropathy. J Neurol Sci. 2019;397:141–5. https://doi.org/10.1016/j.jns.2018.12.036.CrossRefPubMed

30.

Viala K, Maisonobe T, Stojkovic T, et al. A current view of the diagnosis, clinical variants, response to treatment and prognosis of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2010;15(1):50–6. https://doi.org/10.1111/j.1529-8027.2010.00251.x.CrossRefPubMed

31.

Divino V, Mallick R, DeKoven M, et al. The economic burden of CIDP in the United States: a case-control study. PLoS One. 2018;13(10):e0206205. https://doi.org/10.1371/journal.pone.0206205.

32.

Michaelides A, Hadden RDM, Sarrigiannis PG, Hadjivassiliou M, Zis P. Pain in chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis. Pain Ther. 2019;8(2):177–85. https://doi.org/10.1007/s40122-019-0128-y.CrossRefPubMedPubMedCentral

33.

Zis P, Sarrigiannis PG, Rao DG, et al. Chronic idiopathic axonal polyneuropathy: prevalence of pain and impact on quality of life. Brain Behav. 2019;9(1):e01171. https://doi.org/10.1002/brb3.1171.

34.

Faurot KR, Jonsson Funk M, Pate V, et al. Using claims data to predict dependency in activities of daily living as a proxy for frailty. Pharmacoepidemiol Drug Saf. 2015;24(1):59–66. https://doi.org/10.1002/pds.3719.CrossRefPubMed

35.

Thomas S, Chirila C, Ritchey M. Visualization of patient electronic records to support exploratory analysis and variable derivation of categorical data. Presented at the 25th Annual Southeast SASI Users Group (SESUG) Conference; November 2017. Cary, NC.

36.

Latov N, Deng C, Dalakas MC, et al. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol. 2010;67(7):802–7. https://doi.org/10.1001/archneurol.2010.105.CrossRefPubMed

37.

Williams T, Polsen M, Runken M. Real-world use of IVIG in US regional healthcare plans. J Managed Care Spec Pharm. 2018;24:S103.

38.

Daniel GW, Menis M, Sridhar G, et al. Immune globulins and thrombotic adverse events as recorded in a large administrative database in 2008 through 2010. Transfusion. 2012;52(10):2113–21. https://doi.org/10.1111/j.1537-2995.2012.03589.x.CrossRefPubMed

39.

Ekezue BF, Sridhar G, Forshee RA, et al. Occurrence of acute renal failure on the same day as immune globulin product administrations during 2008 to 2014. Transfusion. 2017;57(12):2977–86. https://doi.org/10.1111/trf.14330.CrossRefPubMed

40.

Sridhar G, Ekezue BF, Izurieta HS, et al. Occurrence of hemolytic reactions on the same day as immune globulin product administrations during 2008 to 2014. Transfusion. 2018;58(1):70–80. https://doi.org/10.1111/trf.14384.CrossRefPubMed

41.

Sridhar G, Ekezue BF, Izurieta HS, et al. Immune globulins and same-day thrombotic events as recorded in a large health care database during 2008 to 2012. Transfusion. 2014;54(10):2553–65. https://doi.org/10.1111/trf.12663.CrossRefPubMed

Title: Intravenous Immunoglobulin Treatment Patterns and Outcomes in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A US Claims Database Analysis
Authors: Colin Anderson-Smits
Mary E. Ritchey
Zhongwen Huang
Shailesh Chavan
Nizar Souayah
Hakan Ay
J. Bradley Layton
Publication date: 12-05-2023
Publisher: Springer Healthcare
Published in: Neurology and Therapy / Issue 4/2023
Print ISSN: 2193-8253
Electronic ISSN: 2193-6536
DOI: https://doi.org/10.1007/s40120-023-00478-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Intravenous Immunoglobulin Treatment Patterns and Outcomes in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A US Claims Database Analysis

Abstract

Introduction

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2023

Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in England

Central Versus Peripheral Drug Exposure Ratio, a Key Differentiator for Siponimod Over Fingolimod?

Otogenic Cerebral Sinus Thrombosis in Children: A Narrative Review

Effect of Intravenous Thrombolytic Dose of Alteplase on Long-Term Prognosis in Patients with Acute Ischemic Stroke

Dietary Patterns and Their Associations with Symptom Levels Among People with Multiple Sclerosis: A Real-World Digital Study

Genetic Predisposition to Periodontitis and Risk of Migraine: A Two-Sample Mendelian Randomization Study